ReviewCirculation research2026
Triglyceride-Rich Lipoprotein Metabolism and Cardiovascular Risk in Diabetes: Bedside to Bench to Bedside.
Review in Circulation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kidney-Vascular Metabolic Crosstalk: Altered Lipoproteins in CKD.Circulation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Type 1 diabetes and type 2 diabetes are associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), manifested as myocardial infarction, ischemic stroke, and peripheral artery disease. The increased ASCVD risk in diabetes cannot be fully explained by traditional risk factors. This review highlights the dysregulation of TRLs (triglyceride-rich lipoproteins; VLDL [very low-density lipoprotein] and chylomicrons), and their remnants, as contributors to ASCVD risk in diabetes by examining 6 typical clinical cases integrated with mechanistic data obtained in preclinical models. Type 2 diabetes is often associated with insulin resistance and increased hepatic secretion of VLDL particles, which are enlarged by an increased lipid load, increased intestinal secretion of chylomicrons, and reduced hepatic clearance of both VLDL and chylomicron remnants. The increased levels of TRLs in turn contribute to the predominance of smaller, denser LDL (low-density lipoprotein) particles and smaller cholesterol-depleted HDL (high-density lipoprotein) particles compared with people without diabetes. When type 2 diabetes occurs in individuals with genetic variants causing altered function of proteins stimulating TRL clearance (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.